The secondary explosive RDX (1,3,5-trinitrohexahydro-1,3,5-triazine) has five known polymorphic forms, though only the α and β phases are observable at room temperature and pressure. Many literature reports suggest that the metastable β-RDX polymorph is extremely rare due to the limited number of solvents from which it can be grown and its facile conversion to the more stable α-RDX form. Herein we show that β-RDX can be consistently obtained using drop cast crystallization methods from a broad range of solvents [acetone, tetrahydrofuran (THF), nitromethane, dimethylsufoxide (DMSO)] and that crystals grown this way remain stable over extended periods of time up to a year. The distribution of α:β crystals as a function of solvent and drop concentration on various modified and unmodified glass surfaces was determined using Raman microscopy. β-RDX was the most prevalent phase deposited from dilute drops regardless of the solvent, though more concentrated DMSO drops tended to give either β or α exclusively. In cases where concomitant growth was observed, β crystals were typically smaller than α-RDX crystals. The morphological and thermal properties of β-RDX crystals were assessed, allowing for the most thorough characterization of the physical–chemical properties of this metastable phase to date. Mechanistic differences in the decomposition pathway of α-RDX and β-RDX single crystals upon exposure to electromagnetic radiation suggest some interesting intrinsic differences in their material properties.
No takes yet. Share an insight, caveat, or question.
Goldberg et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: